1. Impact of genotype on clinical course in sickle cell disease and the utility of neutrophil-lymphocyte ratio: a ten-year single-institution experience.
- Author
-
Mathavan A, Mathavan A, Mathavan M, Krekora U, Winer AJ, Altshuler E, Wnek R, Hones K, Thaper A, Artola R, Pucci L, Haley P, Carter D, Snead W, Manfrini D, Leach DF 3rd, DeLaune JD, and Mandernach MW
- Subjects
- Humans, Retrospective Studies, Neutrophils, Genotype, Lymphocytes, Disease Progression, Anemia, Sickle Cell diagnosis, Anemia, Sickle Cell genetics, Anemia, Sickle Cell therapy, Thalassemia
- Abstract
Background: Sickle cell disease (SCD) is a diverse group of blood disorders with significant global disease burden. Contemporary interest in the underlying inflammatory paradigm of SCD has emphasized the role of the neutrophil-lymphocyte ratio (NLR) as a prognostic inflammatory marker., Methods: We retrospectively reviewed 268 hospitalized patients with SCDs of different genotypes (HbSS, HbSβ
0 thalassemia, HbSβ+ thalassemia, and HbSC), totaling 3329 hospital admissions over a 10-year period. Patients were stratified into SS/Sβ0 and Sβ+ /SC groups for statistical analysis of parameters collected at steady state and at hospital admission., Results: At steady state, per unit increase of hemoglobin values was associated with reduced odds of ≥ 2 hospital admissions per year in SS/Sβ0 and Sβ+ /SC groups; per unit increase in platelet count and white blood cell count was associated with increased odds only in the SS/Sβ0 group. The NLR had no association in either group. During admission, a cutoff of NLR = 3.5 discerned infection with a sensitivity of 60% and specificity of 57%. Performance improved when excluding patients on outpatient hydroxyurea therapy (cutoff of NLR = 3.5; sensitivity of 68% and specificity of 64%)., Conclusion: This study supports the utility of NLR as an accessible adjunctive clinical tool in SCD prognostication.- Published
- 2023
- Full Text
- View/download PDF